Yoona Kim, PharmD, PhD, co-founder, CEO of Arine Inc., talked about the relationship between racial health disparities and medication non-adherence, and how artificial intelligence can help improve adherence between groups most affected such as Black, Latino and Asian populations.
In this interview Yoona Kim, PharmD, PhD, co-founder, CEO of Arine Inc., addressed a few topics on the relationship between racial health disparities and medication adherence. Kim also shared positive outcomes in this relationship through a partnership with SCAN Health and the adoption of AI practices.
When describing the relationship between the two, Kim first noted that medication adherence is very important to manage chronic conditions and that medications for them need to be taken on a regular basis.
"Due to many of the social and economic inequities that have occurred over time, there's certainly disparities in medication adherence among certain races and ethnicities," she said. "That's due to lack of trust, language barriers, economic barriers. In SCAN's population, what we saw was there was a 3% gap in medication adherence between the Black and Latinx members versus white members — it was 85% versus 88%. In adherence, that is a significant gap.
"We see this across many of our customers as well, where one of the predictors of non-adherence happens to be that race and ethnicity data."
Kim shared how AI tools have helped combat this issue.
"So AI allows us to take advantage of all this (economic, cultural, social, behavioral and demographic) data that's there and look to understand the causes of disparities, and understand the reasons for things like non-adherence so that we can further personalize care," she said. "The main things we do (in our platform), we have models that target the right members for outreach and models that target the right intervention; AI helps with all of that. Then what we're doing is we're looking at which interventions are leading to the best outcomes..."
This practice includes using a model called adherence trajectory with the data. This tool or model allows professionals to look at patterns of adherence, which members are going in and out of.
From there, interventions can be built to personalize care around the barriers needed to be most met for patients.
Innovations in Pharmacy and Its Impact on Managed Care
March 29th 2023Managing Directors of L.E.K. Consulting, Joe Johnson, Todd Clark and Brendan Mitchell introduce the innovations happening in pharmacy, more specifically disruptive innovations, and how they affect managed care. The team explained some of the innovations to be on the lookout for in the future, also.
Read More
Tis Full and Very, Very Expensive: the 2023 Specialty Drug Pipeline | AMCP 2023
March 24th 2023Specialty drugs are expected to comprise 80% of the FDA approvals this year. Among them are gene therapies for hemophilia A and Duchenne muscular dystrophy priced at between $2 million and $3 million.
Read More
Some Things Old, Many Things New When It Comes to Payer PDT Review | AMCP 2023
March 24th 2023Coverage decisions about prescription digital therapeutics may take payers out of their comfort zones and require new processes and subject matter experts, according to members of a panel at the AMCP annual meeting. But P&T committees are likely to still be central to the process.
Read More
For Weight Loss, Off-Label GLP-1s Are Increasingly the Chosen Ones | AMCP 2023
March 24th 2023They are the trendy way to lose weight and payers have been noticing an increase in GLP-1 claims. An analysis of the pharmacy and healthcare claims of a small commercial health plan in Texas documents the growth in the off-label usage of the GLP-1s, such as Ozempic, for weight loss.
Read More
2 Clarke Drive
Cranbury, NJ 08512